Multiple Sclerosis Drug Trial Halted After Patient Dies

Shares of Elan fell 57 percent in early trading while Biogen Idec's shares fell 40 percent. The drug, which was approved last November, was widely expected to become the world's leading multiple sclerosis treatment.